Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26
Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) and FOLFIRI…
Screening improves early detection of colorectal cancer
More cases of colorectal cancer are detected at an early stage with screening. This is according to new research based on data from over 278,000 60-year-olds, who were randomly selected…
Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients
For some patients with gastrointestinal (GI) cancers like colorectal and pancreatic cancer, chemotherapy can cause severe, sometimes life-threatening side effects in those who carry certain genetic variants that can impact…
Alcohol-fueled cancer deaths are on the rise in the US #ASCO25
A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time…
Bacterial vaccine shows promise as cancer immunotherapy
Columbia researchers have engineered probiotic bacteria that educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines that take advantage of bacteria’s…
How does aspirin help prevent colorectal cancer development and progression?
Long-term daily use of aspirin can help to prevent the development and progression of colorectal cancer, but the mechanisms involved have been unclear. New research has revealed that aspirin may…